Smith S R, Galloway M J, Reilly J T, Davies J M
University Department of Haematology, Royal Liverpool Hospital.
J Clin Pathol. 1988 May;41(5):494-7. doi: 10.1136/jcp.41.5.494.
Twenty neutropenic patients with various haematological disorders were randomised prospectively to receive either intravenous amphotericin B alone or amphotericin B and oral amiloride 5 mg twice a day for treatment of confirmed or suspected fungal infection. Patients receiving amiloride had a significantly higher plasma potassium (p less than 0.01), a significantly lower urinary potassium loss (p less than 0.01), and required significantly less potassium chloride supplementation to maintain their plasma potassium within the normal range (p less than 0.001). Amiloride was well tolerated, had no clinically important side effects, and provided effective control of plasma potassium in patients treated with amphotericin B.
20例患有各种血液系统疾病的中性粒细胞减少患者被前瞻性随机分组，分别接受单独静脉注射两性霉素B或两性霉素B加口服阿米洛利（每日2次，每次5毫克）治疗确诊或疑似真菌感染。接受阿米洛利治疗的患者血浆钾水平显著更高（p<0.01），尿钾丢失显著更低（p<0.01），并且维持血浆钾在正常范围内所需的氯化钾补充量显著更少（p<0.001）。阿米洛利耐受性良好，无临床重要副作用，并且能有效控制接受两性霉素B治疗患者的血浆钾水平。
